The term ‘endocannabinoid’ was originally established in the mid-1990s after the discovery of cellular membrane receptors responsible for psychoactivity in Cannabis, Δ9-tetrahydrocannabinol (THC) and their endogenous ligands (protein receptors). This now indicates a whole new signaling system that comprises of cannabinoid receptors, endogenous ligands, and enzymes that work concurrently with almost all other physiological systems.

This system seems to be involved in an increasing number of pathologies. With novel products already being aimed at the pharmaceutical market in just a little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to be very promising for the future development of therapeutic drugs. 

The endocannabinoid system (ECS) has been said to have a plethora of positive impacts on human physiology. Although much of the science is still in the preliminary stages, recent evidence is uncovering the truth about how important this system is and how it impacts other systems throughout the body.



You may be thinking what is cannabidiol (CBD) exactly? Often times people hear the word “cannabinoid” and they instantly think, THC, MARIJUANA!


The truth is, yes, being that THC contains psychoactive properties it was one of the first to be highlighted in the cannabinoid family. However, THC is only one of over 421 chemical compounds that cannabis sativa produces, therefore only less than a half percent of what the plant produces and is capable of.


Yes, I know, it is ironic that the plant produces roughly 420 different chemical compounds and cannabinoids… Which includes over 80 different terpo-phenol profiles which are responsible for the different aromas and therapeutic responses that you can achieve with the usage of ingestible cannabinoids.


Recent literature from the past decade has explained that endocannabinoids have positive implications in achieving homeostasis (balance) within the renal system, gastrointestinal system, hepatic system, immune system, cardiovascular and the central nervous system. This is achieved through binding of these cannabinoids to receptors that are abundant in these systems that I explained above. 


The endocannabinoid system is designed to not only regulate cannabinoid production within the body, but it is also designed to receive external cannabinoids to assist in strengthening the ECS response and in turn regulating other systems more effectively. 



Well, there is still so much work to be done in terms of the research and science to solidify the safety and efficacy of hemp-derived CBD oils. However, there is a broad range of evidence that continues to grow and point toward the effectiveness of CBD as a therapeutic agent. 


It has been nearly three decades since the discovery of the ECS. Recent developments suggest that non-psychotropic phytocannabinoids exert a wide range of pharmacological effects, many of which are of potential therapeutic interest. The most studied among these compounds is CBD, the pharmacological effects of which might be explained by a combination of mechanisms of action. CBD has an extremely safe profile in humans, and it has been clinically evaluated (although preliminary) for the treatment of anxiety, psychosis, and movement disorders. There is good pre-clinical evidence to warrant clinical studies into its use for the treatment of diabetes, ischemia and cancer. 



The design of further clinical trials should: 1) consider the bell-shaped pattern of the dose-response curve that has been observed in pre-clinical pharmacology, and 2) establish if CBD is more effective or has fewer unwanted effects than other medicines. However, the establishment of these guidelines would require advisory from the food and drug administration (FDA).



The pharmacology of THC-V is also intriguing because it has the potential of application in diseases such as chronic liver disease or obesity when it is associated with inflammation, in which CB1 blockade together with some CB2 activation is beneficial. 


Concerning obesity treatment, it will be important in future studies to establish if THC-V is more effective or has fewer unwanted effects than rimonabant. Rimonabant was the first clinically available CB1 receptor antagonist but was withdrawn from the market because of the increased risk of depression.


The plant Cannabis is a source of several other neglected phytocannabinoids such as CBC and CBG. Although the spectrum of pharmacological effects of these compounds is largely unexplored, their potent action at certain receptor sites (TRPA1 and TRPM8) might make these compounds new and attractive tools for pain management.